Pipeline - Cassiopea
https://www.cassiopea.com/product-pipelineCB-06-01 is a novel topical antibiotic currently under development and investigation for acne. It is a topical antibiotic that could provide another option against Cutibacterium acnes bacteria. Science story Many C acnes strains are resistant to commonly prescribed antibiotics for acne.
Investors - Cassiopea
https://www.cassiopea.com/investor-relationsCassiopea S.p.A. is listed on the Swiss stock exchange (ticker: SKIN) with the vision of building a leading, fully integrated dermatology company. Cassiopea, Inc., our United States subsidiary, was created with the mission to commercialize Cassiopea’s products in the United States. For Relevant information about offer, please click here
Home Page - Cassiopea
https://www.cassiopea.comCassiopea, Inc. is a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action to address long-standing and essential dermatological conditions such as acne, androgenetic alopecia (AGA), and genital warts. WHAT’S OUR STORY? We are on a mission to impact patients’ lives.
Company - Cassiopea
https://www.cassiopea.com/companyCassiopea S.p.A. is listed on the Swiss stock exchange (ticker: SKIN) with the vision of building a leading, fully integrated dermatology company. Cassiopea, Inc., our United States subsidiary, was created with the mission to commercialize Cassiopea’s products in the United States.